# Kathleen M Neuzil

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/2145711/publications.pdf

Version: 2024-02-01

| 82 | 16,551 | 172457 | 62596 |
|---|---|---|---|
| papers | citations | 29 h-index | 80 g-index |

| 93 | 93 | 93 | 22774 |
|---|---|---|---|
| all docs | docs citations | times ranked | citing authors |

| # | Article | IF | Citations |
|---|---|---|---|
| 1 | Are Some COVID-19 Vaccines Better Than Others? Interpreting and Comparing Estimates of Efficacy in Vaccine Trials. Clinical Infectious Diseases, 2022, 74, 352-358. | 5.8 | 36 |
| 2 | The Operational Feasibility of Vaccination Programs Targeting Influenza Risk Groups in the World Health Organization (WHO) African and South-East Asian Regions. Clinical Infectious Diseases, 2022, 74, 227-236. | 5.8 | 3 |
| 3 | The value of vaccine programme impact monitoring during the COVID-19 pandemic. Lancet, The, 2022, 399, 119-121. | 13.7 | 6 |
| 4 | Homologous and Heterologous Covid-19 Booster Vaccinations. New England Journal of Medicine, 2022, 386, 1046-1057. | 27.0 | 418 |
| 5 | Prevention and Control of COVID-19: Where do we go from here?. Clinical Infectious Diseases, 2022, , . | 5.8 | 0 |
| 6 | Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial. Science, 2022, 375, 43-50. | 12.6 | 788 |
| 7 | Risk of Severe Acute Respiratory Syndrome Coronavirus 2 Acquisition Is Associated With Individual Exposure but Not Community-Level Transmission. Journal of Infectious Diseases, 2022, 226, 225-235. | 4.0 | 4 |
| 8 | Trajectory of Viral RNA Load Among Persons With Incident SARS-CoV-2 G614 Infection (Wuhan Strain) in Association With COVID-19 Symptom Onset and Severity. JAMA Network Open, 2022, 5, e2142796. | 5.9 | 57 |
| 9 | Estimating the effect of vaccination on antimicrobial-resistant typhoid fever in 73 countries supported by Gavi: a mathematical modelling study. Lancet Infectious Diseases, The, 2022, 22, 679-691. | 9.1 | 32 |
| 10 | Self-Assessed Severity as a Determinant of COVID-19 Symptom Specificity: A Longitudinal Cohort Study. Clinical Infectious Diseases, 2022, , . | 5.8 | 0 |
| 11 | Detection and kinetics of subgenomic SARS-CoV-2 RNA viral load in longitudinal diagnostic RNA positive samples. Journal of Infectious Diseases, 2022, , . | 4.0 | 4 |
| 12 | WHO preferred product characteristics for monoclonal antibodies for passive immunization against respiratory syncytial virus (RSV) disease in infants â€“ Key considerations for global use. Vaccine, 2022, 40, 3506-3510. | 3.8 | 20 |
| 13 | Understanding COVID-19 through human challenge models. Nature Medicine, 2022, 28, 903-904. | 30.7 | 4 |
| 14 | Safety and immunogenicity of monovalent H7N9 influenza vaccine with AS03 adjuvant given sequentially or simultaneously with a seasonal influenza vaccine: A randomized clinical trial. Vaccine, 2022, 40, 3253-3262. | 3.8 | 3 |
| 15 | Multi-site observational maternal and infant COVID-19 vaccine study (MOMI-vax): a study protocol. BMC Pregnancy and Childbirth, 2022, 22, 402. | 2.4 | 4 |
| 16 | Clinical endpoints to inform vaccine policy: A systematic review of outcome measures from pediatric influenza vaccine efficacy trials. Vaccine, 2022, 40, 4339-4347. | 3.8 | 1 |
| 17 | Antinucleocapsid Antibodies After SARS-CoV-2 Infection in the Blinded Phase of the Randomized, Placebo-Controlled mRNA-1273 COVID-19 Vaccine Efficacy Clinical Trial. Annals of Internal Medicine, 2022, 175, 1258-1265. | 3.9 | 63 |
| 18 | Estimates of Inactivated Influenza Vaccine Effectiveness Among Children in Senegal: Results From 2 Consecutive Cluster-Randomized Controlled Trials in 2010 and 2011. Clinical Infectious Diseases, 2021, 72, e959-e969. | 5.8 | 6 |

| # | Article | IF | Citations |
|---|---|---|---|
| 19 | Durability of Responses after SARS-CoV-2 mRNA-1273 Vaccination. New England Journal of Medicine, 2021, 384, 80-82. | 27.0 | 665 |
| 20 | Safety and immunogenicity of co-administration of meningococcal type A and measlesâ€“rubella vaccines with typhoid conjugate vaccine in children aged 15â€“23 months in Burkina Faso. International Journal of Infectious Diseases, 2021, 102, 517-523. | 3.3 | 20 |
| 21 | Clinical Endpoints for Evaluating Efficacy in COVID-19 Vaccine Trials. Annals of Internal Medicine, 2021, 174, 221-228. | 3.9 | 86 |
| 22 | Hydroxychloroquine as Postexposure Prophylaxis to Prevent Severe Acute Respiratory Syndrome Coronavirus 2 Infection. Annals of Internal Medicine, 2021, 174, 344-352. | 3.9 | 73 |
| 23 | The Impact of Vaccination on Coronavirus Disease 2019 (COVID-19) Outbreaks in the United States. Clinical Infectious Diseases, 2021, 73, 2257-2264. | 5.8 | 376 |
| 24 | Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. New England Journal of Medicine, 2021, 384, 403-416. | 27.0 | 7,910 |
| 25 | Evaluation of Typhoid Conjugate Vaccine Effectiveness in Ghana (TyVEGHA) Using a Cluster-Randomized Controlled Phase IV Trial: Trial Design and Population Baseline Characteristics. Vaccines, 2021, 9, 281. | 4.4 | 4 |
| 26 | The potential effects of deploying SARS-Cov-2 vaccines on cold storage capacity and immunization workload in countries of the WHO African Region. Vaccine, 2021, 39, 2165-2176. | 3.8 | 11 |
| 27 | National routine adult immunisation programmes among World Health Organization Member States: an assessment of health systems to deploy COVID-19 vaccines. Eurosurveillance, 2021, 26, . | 7.0 | 23 |
| 28 | Antibody Persistence through 6 Months after the Second Dose of mRNA-1273 Vaccine for Covid-19. New England Journal of Medicine, 2021, 384, 2259-2261. | 27.0 | 603 |
| 29 | Safety and immunogenicity of Vi-typhoid conjugate vaccine co-administration with routine 9-month vaccination in Burkina Faso: A randomized controlled phase 2 trial. International Journal of Infectious Diseases, 2021, 108, 465-472. | 3.3 | 14 |
| 30 | Cost-effectiveness of infant respiratory syncytial virus preventive interventions in Mali: A modeling study to inform policy and investment decisions. Vaccine, 2021, 39, 5037-5045. | 3.8 | 17 |
| 31 | Protection by vaccination of children against typhoid fever with a Vi-tetanus toxoid conjugate vaccine in urban Bangladesh: a cluster-randomised trial. Lancet, The, 2021, 398, 675-684. | 13.7 | 77 |
| 32 | A Deferred-Vaccination Design to Assess Durability of COVID-19 Vaccine Effect After the Placebo Group Is Vaccinated. Annals of Internal Medicine, 2021, 174, 1118-1125. | 3.9 | 15 |
| 33 | Prospects of Future Typhoid and Paratyphoid Vaccines in Endemic Countries. Journal of Infectious Diseases, 2021, 224, S770-S774. | 4.0 | 16 |
| 34 | Safety and Efficacy of a Typhoid Conjugate Vaccine in Malawian Children. New England Journal of Medicine, 2021, 385, 1104-1115. | 27.0 | 82 |
| 35 | Typhoid Conjugate Vaccines: Advancing the Research and Public Health Agendas. Journal of Infectious Diseases, 2021, 224, S781-S787. | 4.0 | 19 |
| 36 | Efficacy of the mRNA-1273 SARS-CoV-2 Vaccine at Completion of Blinded Phase. New England Journal of Medicine, 2021, 385, 1774-1785. | 27.0 | 402 |

| # | Article | IF | Citations |
|---|---|---|---|
| 37 | A Novel Recombinant Influenza Virus Neuraminidase Vaccine Candidate Stabilized by a Measles Virus Phosphoprotein Tetramerization Domain Provides Robust Protection from Virus Challenge in the Mouse Model. MBio, 2021, 12, e0224121. | 4.1 | 21 |
| 38 | LB6. Asymptomatic Infection and Duration of Viral Shedding in Symptomatic Breakthrough Infections in a Phase 3 Study of AZD1222 (ChAdOx1 nCoV-19). Open Forum Infectious Diseases, 2021, 8, S804-S804. | 0.9 | 1 |
| 39 | Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial. Science, 2021, , eab3435. | 12.6 | 145 |
| 40 | Immunogenicity and safety of different dosing schedules of trivalent inactivated influenza vaccine in pregnant women with HIV: a randomised controlled trial. Lancet HIV,the, 2020, 7, e91-e103. | 4.7 | 16 |
| 41 | Immunogenicity of seasonal inactivated influenza and inactivated polio vaccines among children in Senegal: Results from a cluster-randomized trial. Vaccine, 2020, 38, 7526-7532. | 3.8 | 1 |
| 42 | PhaseÂI/II study of COVID-19 RNA vaccine BNT162b1 in adults. Nature, 2020, 586, 589-593. | 27.8 | 1,197 |
| 43 | Early Insights From Clinical Trials of Typhoid Conjugate Vaccine. Clinical Infectious Diseases, 2020, 71, S155-S159. | 5.8 | 4 |
| 44 | Accelerating Development of SARS-CoV-2 Vaccines â€" The Role for Controlled Human Infection Models. New England Journal of Medicine, 2020, 383, e63. | 27.0 | 73 |
| 45 | Morbidity and Mortality of Typhoid Intestinal Perforation Among Children in Subâ€Saharan Africa 1995â€“2019: A Scoping Review. World Journal of Surgery, 2020, 44, 2892-2902. | 1.6 | 16 |
| 46 | LB-17. Efficacy of Hydroxychloroquine (HCQ) for Post-exposure Prophylaxis to Prevent Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection: A Blinded, Randomized, Controlled Trial. Open Forum Infectious Diseases, 2020, 7, S851-S852. | 0.9 | 0 |
| 47 | A public health evaluation of 13-valent pneumococcal conjugate vaccine impact on adult disease outcomes from a randomized clinical trial in the Netherlands. Vaccine, 2019, 37, 5777-5787. | 3.8 | 41 |
| 48 | Influenza vaccine programs for children in low- and middle-income countries: current status and way forward. Expert Review of Vaccines, 2019, 18, 711-724. | 4.4 | 5 |
| 49 | Maternal immunization in Malawi: A mixed methods study of community perceptions, programmatic considerations, and recommendations for future planning. Vaccine, 2019, 37, 4568-4575. | 3.8 | 12 |
| 50 | Reply to Skowronski and De Serres. Clinical Infectious Diseases, 2019, 69, 2231-2232. | 5.8 | 1 |
| 51 | The Impact of Influenza Vaccine: Itâ€™s the Size of the Glass. Clinical Infectious Diseases, 2019, 69, 1854-1855. | 5.8 | 2 |
| 52 | Cost-effectiveness of routine and campaign use of typhoid Vi-conjugate vaccine in Gavi-eligible countries: a modelling study. Lancet Infectious Diseases, The, 2019, 19, 728-739. | 9.1 | 54 |
| 53 | Influenza Immunization in Low- and Middle-Income Countries: Preparing for Next-Generation Influenza Vaccines. Journal of Infectious Diseases, 2019, 219, S97-S106. | 4.0 | 43 |
| 54 | Introduction of Typhoid Conjugate Vaccines in Africa and Asia. Clinical Infectious Diseases, 2019, 68, S27-S30. | 5.8 | 19 |

| # | Article | IF | Citations |
|---|---|---|---|
| 55 | Impact of Rotavirus Vaccine Introduction in Children Less Than 2 Years of Age Presenting for Medical Care With Diarrhea in Rural Matlab, Bangladesh. Clinical Infectious Diseases, 2019, 69, 2059-2070. | 5.8 | 8 |
| 56 | Future epidemiological and economic impacts of universal influenza vaccines. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 20786-20792. | 7.1 | 26 |
| 57 | The Effect of Preexisting Immunity on Virus Detection and Immune Responses in a Phase II, Randomized Trial of a Russian-Backbone, Live, Attenuated Influenza Vaccine in Bangladeshi Children. Clinical Infectious Diseases, 2019, 69, 786-794. | 5.8 | 20 |
| 58 | Immunogenicity and Viral Shedding of Russian-Backbone, Seasonal, Trivalent, Live, Attenuated Influenza Vaccine in a Phase II, Randomized, Placebo-Controlled Trial Among Preschool-Aged Children in Urban Bangladesh. Clinical Infectious Diseases, 2019, 69, 777-785. | 5.8 | 18 |
| 59 | How do we best prevent influenza in young children?. Lancet Respiratory Medicine,the, 2018, 6, 317-319. | 10.7 | 1 |
| 60 | Evaluation of a Booster Dose of Pentavalent Rotavirus Vaccine Coadministered With Measles, Yellow Fever, and Meningitis A Vaccines in 9-Month-Old Malian Infants. Journal of Infectious Diseases, 2018, 218, 606-613. | 4.0 | 23 |
| 61 | Traditional cooking practices and preferences for stove features among women in rural Senegal: Informing improved cookstove design and interventions. PLoS ONE, 2018, 13, e0206822. | 2.5 | 28 |
| 62 | Immunogenicity and safety of MF59-adjuvanted and full-dose unadjuvanted trivalent inactivated influenza vaccines among vaccine-naÃ¯ve children in a randomized clinical trial in rural Senegal. Vaccine, 2018, 36, 6424-6432. | 3.8 | 11 |
| 63 | Safety and immunogenicity of a pentavalent meningococcal conjugate vaccine containing serogroups A, C, Y, W, and X in healthy adults: a phase 1, single-centre, double-blind, randomised, controlled study. Lancet Infectious Diseases, The, 2018, 18, 1088-1096. | 9.1 | 63 |
| 64 | Implementation of maternal influenza immunization in El Salvador: Experiences and lessons learned from a mixed-methods study. Vaccine, 2018, 36, 4054-4061. | 3.8 | 16 |
| 65 | Rotavirus vaccine effectiveness in low-income settings: An evaluation of the test-negative design. Vaccine, 2017, 35, 184-190. | 3.8 | 37 |
| 66 | Reaching every child with rotavirus vaccine: Report from the 10th African rotavirus symposium held in Bamako, Mali. Vaccine, 2017, 35, 5511-5518. | 3.8 | 5 |
| 67 | Estimating the full public health value of vaccination. Vaccine, 2017, 35, 6255-6263. | 3.8 | 52 |
| 68 | Influenza Vaccines for Older Persons: Progress and Pitfalls. Journal of Infectious Diseases, 2017, 216, 397-398. | 4.0 | 1 |
| 69 | Incidence of laboratory-confirmed influenza disease among infants under 6 months of age: a systematic review. BMJ Open, 2017, 7, e016526. | 1.9 | 22 |
| 70 | Effectiveness of a live oral human rotavirus vaccine after programmatic introduction in Bangladesh: A cluster-randomized trial. PLoS Medicine, 2017, 14, e1002282. | 8.4 | 46 |
| 71 | Maternal influenza immunization in Malawi: Piloting a maternal influenza immunization program costing tool by examining a prospective program. PLoS ONE, 2017, 12, e0190006. | 2.5 | 16 |
| 72 | Efficacy of a Russian-backbone live attenuated influenza vaccine among children in Senegal: a randomised, double-blind, placebo-controlled trial. The Lancet Global Health, 2016, 4, e955-e965. | 6.3 | 57 |

| # | Article | IF | Citations |
|---|---|---|---|
| 73 | The Art and Science of Delivering Influenza Vaccines. Journal of Infectious Diseases, 2016, 214, 1129-1131. | 4.0 | 1 |
| 74 | Preventing Shingles and Its Complications in Older Persons. New England Journal of Medicine, 2016, 375, 1079-1080. | 27.0 | 13 |
| 75 | Rotavirus vaccination and intussusception â€“ Science, surveillance, and safety: A review of evidence and recommendations for future research priorities in low and middle income countries. Human Vaccines and Immunotherapeutics, 2016, 12, 2580-2589. | 3.3 | 47 |
| 76 | Progress toward a Respiratory Syncytial Virus Vaccine. Vaccine Journal, 2016, 23, 186-188. | 3.1 | 61 |
| 77 | Community-acquired diarrhoea in a world with rotavirus vaccine: a glimpse into the future. The Lancet Global Health, 2015, 3, e510-e511. | 6.3 | 10 |
| 78 | A proposed framework for evaluating and comparing efficacy estimates in clinical trials of new rotavirus vaccines. Vaccine, 2014, 32, A179-A184. | 3.8 | 11 |
| 79 | Effect of Human Rotavirus Vaccine on Severe Diarrhea in African Infants. New England Journal of Medicine, 2010, 362, 289-298. | 27.0 | 800 |
| 80 | Efficacy of pentavalent rotavirus vaccine against severe rotavirus gastroenteritis in infants in developing countries in Asia: a randomised, double-blind, placebo-controlled trial. Lancet, The, 2010, 376, 615-623. | 13.7 | 660 |
| 81 | Efficacy of pentavalent rotavirus vaccine against severe rotavirus gastroenteritis in infants in developing countries in sub-Saharan Africa: a randomised, double-blind, placebo-controlled trial. Lancet, The, 2010, 376, 606-614. | 13.7 | 626 |
| 82 | Using social contact data to improve the overall effect estimate of a clusterâ€randomized influenza vaccination program in Senegal. Journal of the Royal Statistical Society Series C: Applied Statistics, 0, , . | 1.0 | 0 |